Matthew Rousculp is an experienced healthcare professional currently serving as Vice President of Real World Evidence at Novavax Inc since January 2022. Prior to this role, Rousculp held several leadership positions at Takeda, the NEWDIGS Initiative at MIT, and GSK, where responsibilities included new product planning, value and outcomes management, and healthcare delivery innovation. Rousculp has extensive experience in health outcomes research, demonstrated through previous roles at MedImmune and Eli Lilly and Company. Academically, Rousculp earned a PhD in Administration-Health Services and an MPH in Epidemiology from the University of Alabama at Birmingham, and a BA in Biological Sciences from Rutgers University. Additional education includes certificates from Harvard Medical School in immunology and artificial intelligence in healthcare.
This person is not in any teams
This person is not in any offices